BYSI:NSD-BeyondSpring Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 12.66

Change

-0.46 (-3.51)%

Market Cap

USD 0.51B

Volume

0.49M

Average Target Price

USD 27.50 (+117.22%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a programmed cell death protein 1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody to treat small cell lung cancer; and death protein 1 or programmed death-ligand 1, an antibodies and radiation or chemotherapy for the treatment of multiple cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform using ubiquitin mediated protein degradation pathway. BeyondSpring Inc. has collaboration agreements with the Fred Hutchinson Cancer Research Center and the University of Washington. The company was founded in 2010 and is headquartered in New York, New York.

Company Website : http://www.beyondspringpharma.com

Address : 28 Liberty Street, New York, NY, United States, 10005

Employees : 61

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.60

52 Week High : 18.75

Short Ratio : 1.96

52 Week Low : 9.38

Shorted Shares : 987,479

200 Day Moving Average : 13.01

Shorted Shares Previous Month : 923,876

50 Day Moving Average : 11.83

Shares Held By Insiders : 715.45%

Short Percentage : 3.00%

Shares Held by Institutions : 6.2%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-1.05 (-0.44%)

 USD62.06B 23.39 18.26
REGN Regeneron Pharmaceuticals, Inc

+2.30 (+0.43%)

 USD57.14B 19.62 14.64
MRNA Moderna, Inc

-1.96 (-1.47%)

 USD52.62B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

+1.87 (+1.18%)

 USD34.53B 36.64 33.83
SGEN Seagen Inc

-3.03 (-1.63%)

 USD33.25B 70.16 70.76
BGNE BeiGene, Ltd

+17.51 (+4.90%)

 USD32.53B N/A N/A
RPRX Royalty Pharma plc

+0.74 (+1.47%)

 USD31.52B 22.60 11.90
GMAB Genmab A/S

-0.01 (-0.02%)

 USD28.49B 26.59 3.08
BNTX BioNTech SE

+3.01 (+2.85%)

 USD25.39B -99,999.99 N/A
INCY Incyte Corporation

+3.99 (+4.25%)

 USD20.56B 47.64 35.20

ETFs Containing BYSI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.77% 25% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.77% 25% F 39% F
Trailing 12 Months  
Capital Gain -22.24% 23% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.24% 22% F 13% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -16.49% 20% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.49% 20% F 10% F
Risk Return Profile  
Volatility (Standard Deviation) 20.55% 94% A 67% D+
Risk Adjusted Return -80.21% 11% F 6% F
Market Capitalization 0.51B 58% F 53% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 20.12 9% F 7% F
Price / Cash Flow Ratio -10.66 59% F 78% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -267.71% 9% F 3% F
Return on Invested Capital -336.23% 4% F 2% F
Return on Assets -103.49% 3% F 1% F
Debt to Equity Ratio 4.74% 72% C- 83% B
Technical Ratios  
Short Ratio 1.96 60% D- 60% D-
Short Percent 3.57% 72% C- 48% F
Beta 0.60 86% B 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector